PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild‑type (WT) KRAS metastatic colorectal cancer (mCRC).
Lee Steven Schwartzberg
Consultant or Advisory Role - Amgen
Fernando Rivera
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
Meinolf Karthaus
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Gianpiero Fasola
Consultant or Advisory Role - Amgen
Jean-Luc Canon
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Expert Testimony - Amgen
Hua Yu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen